{
  "pmcid": "11634001",
  "sha256": "83b7626759db68cd087ef45bbe9df6eb96d2b23c32250e0ed3f140178545ede3",
  "timestamp_utc": "2025-11-09T23:18:22.116113+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.801037634408601,
    "reading_ease": 35.30155645161295,
    "word_count": 279
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Systematic Review of Supraglottic Airway Devices for Blind Endotracheal Intubation: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Randomisation methods and allocation concealment were assessed"
      },
      "Participants": {
        "score": 2,
        "evidence": "The study setting included various countries, and participants were anesthesiologists, paramedics, and other healthcare professionals."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The Fastrach Intubating Laryngeal Mask Airway (LMA Fastrach), i-gel, Air-Q, and S.A.L.T. were the most used SGDs."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aims to evaluate the effectiveness of supraglottic airway devices (SGDs) for blind endotracheal intubation (ETI) in patients under general anesthesia and simulation manikins."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcomes were the success rate of blind ETI and intubation time."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation methods and allocation concealment were assessed"
      },
      "Blinding": {
        "score": 0,
        "evidence": "blinding was not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "SGDs with the highest overall success rates were i-gel, S.A.L.T., LMA Fastrach, and single-use LMA Fastrach, achieving success rates greater than 90%."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "The study was not registered"
      },
      "Funding": {
        "score": 0,
        "evidence": "funding sources were not disclosed"
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}